It exists as a research compound, purchasable for research purposes
It has been approved by the FDA to treat visceral adiposity (excessive fat around the midsection) in HIV-infected patients with lipodystrophy [5]
BPC-157 (Body Protection Compound) 500MCG 2
Kunst LR, Garcia MV, Machado AK, et al
Immune Defense Blend (LL 37/Thymosin Alpha-1) Blending LL-37 and Thymosin Alpha-1 creates a powerful combination for immune support, antimicrobial defense, and overall healing
Preclinical toxicology in standard models reports low acute toxicity at studied doses, but absence of extensive human clinical trial data precludes definitive statements on safety, tolerability, drug interactions, and longterm effects in humans